[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338912-105":59,"doc-detail-338912-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","18ffdg-petctavid-discordant-volume-as-a-biomarker-in-patients-with-gastroenteropancreatic-neuroendocrine-neoplasms-a-multicenter-study","[18F]FDG PET/CT–Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms - A Multicenter Study","","[18F]FDG PET/CT–avid discordant disease (discordant [18F]FDG-avid/non–[68Ga]Ga-DOTATATE–avid) predicts poor prognosis in neuroendocrine neoplasms, but the clinical value of discordant tumor volume is unclear. This multicenter retrospective study evaluated paired [18F]FDG and [68Ga]Ga-DOTATATE PET/CT in advanced gastroenteropancreatic neuroendocrine neoplasms, using NETPET scoring and contouring with an [18F]FDG SUV cutoff of 4. Total discordant volume (TDV) stratified patients and was assessed against overall survival.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/18ffdg-petctavid-discordant-volume-as-a-biomarker-in-patients-with-gastroenteropancreatic-neuroendocrine-neoplasms-a-multicenter-study/338912/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/18ffdg-petctavid-discordant-volume-as-a-biomarker-in-patients-with-gastroenteropancreatic-neuroendocrine-neoplasms-a-multicenter-study/338912.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What discordant PET/CT pattern was investigated in this study?","Question",{"text":113,"@type":114},"The study focused on discordant disease defined as [18F]FDG-avid but non–[68Ga]Ga-DOTATATE–avid lesions in patients with advanced gastroenteropancreatic neuroendocrine neoplasms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was discordant tumor volume (TDV) measured?",{"text":118,"@type":114},"Discordant lesions were identified using the NETPET score and contoured using a flat [18F]FDG SUV cutoff of 4. TDV was calculated as the sum of the volumes of discordant lesions.",{"name":120,"@type":111,"acceptedAnswer":121},"What was the relationship between TDV and overall survival?",{"text":122,"@type":114},"Overall survival was longer in the low-TDV cohort than in the high-TDV cohort, supporting TDV as a potential prognostic biomarker in GEPNENs.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338912,1790168492,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","[ 18F]FDG PET/CT–Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study  \nDavid L. Chan 1,2, Aimee R. Hayes3, Ioannis Karfis4, Alice Conner1, Magdalena Mileva4, Elizabeth Bernard5, Geoffrey Schembri5, Shaunak Navalkissoor3,6, Gopinath Gnanasegaran3,6, Nick Pavlakis 1,2, Clmentine Marin4, Bruno Vanderlinden7, Patrick Flamen4, Paul Roach5, Martyn E. Caplin3, Christos Toumpanakis3, and Dale L. Bailey 1,5  \n1Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; 2Medical Oncology, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia; 3Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom; 4Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Ho^pital Universitaire de Bruxelles, Universit Libre de Bruxelles, Brussels, Belgium; 5Nuclear Medicine, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia; 6Nuclear Medicine, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom; and 7Medical Physics Department, Institut Jules Bordet, ENETS Centre of Excellence, Ho^pital Universitaire de Bruxelles, Universit Libre de Bruxelles, Brussels, Belgium  \n[18F]FDG PET/CT and [68Ga]Ga-DOTATATE PET/CT are both used to predict tumor biology in neuroendocrine neoplasms. Although the presence of discordant ([18F]FDG-avid/non–[68Ga]Ga-DOTATATE– avid) disease predicts poor prognosis, the signiﬁcance of the volume of such discordant disease remains undetermined. The aim of this study is to investigate discordant tumor volume as a potential biomarker in patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) . Methods: A multicenter retrospective study in patients with advanced GEPNENs and paired [18F]FDG and [68Ga]Ga-DOTATATE PET/CT no more than 85 d apart was conducted. Patients with discordant disease were identiﬁed by the NETPET score, and discordant lesions were contoured with a ﬂat [18F]FDG SUV cutoff of 4 . The primary variable of interest was the total discordant volume (TDV), which was the sum of the volumes of discordant lesions. Patients were dichotomized into high- and low-TDV cohorts by the median value. The primary endpoint was overall survival. Results: In total, 44 patients were included (50% men; median age, 60y), with primary cancers in the pancreas (45%), small bowel (23%), colon (20%), and other (12%) . Of the patients, 5% had grade 1 disease, 48% had grade 2 disease, and 48% had grade 3 disease (24% well differentiated, 67% poorly differentiated, 10% unknown within the grade 3 cohort) . The overall median survival was 14.1mo. Overall survival was longer in the low-TDV cohort than in the high-TDV cohort (median volume, 43 .7 cm3; survival time, 23 .8mo vs. 9.4mo; hazard ratio, 0 .466 [95% CI, 0 .229–0.948]; P 5 0.0221) . Patients with no more than 2 discordant intrahepatic lesions survived longer than those with 2 or more lesions (31.8mo vs. 10.2mo, respectively; hazard ratio, 0 .389 [95% CI, 0 .194–0.779]; P 5 0.0049) . Conclusion: TDVis a potential prognostic biomarker in GEPNENs and should be investigated in future neuroendocrine neoplasm trials.  \nReceived Aug. 17, 2023; revision accepted Oct. 25, 2023 .  \nFor correspondence or reprints, contact David L. Chan (david.chan@sydney. [edu.au](edu.au)) .  \nPublished online Dec. 21, 2023 .  \nImmediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: [https://creativecommons](https://creativecommons). org/licenses/by/4.0/. Details: [http://jnm.snmjournals.org/site/misc/permission](http://jnm.snmjournals.org/site/misc/permission). xhtml.  \nCOPYRIGHT 􀀁 2024 by the Society of Nuclear Medicine and Molecular Imaging.  \nKey Words: prognostic biomarker; discordance; [18","cbCaidqr4GPdeSmC","https://ap.wps.com/l/cbCaidqr4GPdeSmC","pdf",1148305,"English","# Study purpose and methods\n## PET/CT imaging and discordance definition\n## Patient selection and TDV calculation\n# Results and conclusions\n## Survival associations with TDV\n## Intrahepatic lesion count findings\n## Clinical implications","[{\"question\":\"What discordant PET/CT pattern was investigated in this study?\",\"answer\":\"The study focused on discordant disease defined as [18F]FDG-avid but non–[68Ga]Ga-DOTATATE–avid lesions in patients with advanced gastroenteropancreatic neuroendocrine neoplasms.\"},{\"question\":\"How was discordant tumor volume (TDV) measured?\",\"answer\":\"Discordant lesions were identified using the NETPET score and contoured using a flat [18F]FDG SUV cutoff of 4. TDV was calculated as the sum of the volumes of discordant lesions.\"},{\"question\":\"What was the relationship between TDV and overall survival?\",\"answer\":\"Overall survival was longer in the low-TDV cohort than in the high-TDV cohort, supporting TDV as a potential prognostic biomarker in GEPNENs.\"}]","[18F]FDG PET/CT–Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms - A Multicenter Study | PDF",1790026500,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4f1f148e214753e15b96efb82c4953f.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de379ac0eef9d592531ad3048f366179.webp",982,1294,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ed4ab4785da0e12f5b90755cffe50bc.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9928df7bae681827790f6ae13cffa7f4.webp",980,1292]